These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 14625690)

  • 1. The potential therapeutic role of statins in central nervous system autoimmune disorders.
    Stüve O; Youssef S; Dunn S; Slavin AJ; Steinman L; Zamvil SS
    Cell Mol Life Sci; 2003 Nov; 60(11):2483-91. PubMed ID: 14625690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins as potential therapeutic agents in multiple sclerosis.
    Stüve O; Prod'homme T; Youssef S; Dunn S; Neuhaus O; Weber M; Hartung HP; Steinman L; Zamvil SS
    Curr Neurol Neurosci Rep; 2004 May; 4(3):237-44. PubMed ID: 15102350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.
    Youssef S; Stüve O; Patarroyo JC; Ruiz PJ; Radosevich JL; Hur EM; Bravo M; Mitchell DJ; Sobel RA; Steinman L; Zamvil SS
    Nature; 2002 Nov; 420(6911):78-84. PubMed ID: 12422218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins and their potential targets in multiple sclerosis therapy.
    Stüve O; Prod'homme T; Slavin A; Youssef S; Dunn S; Steinman L; Zamvil SS
    Expert Opin Ther Targets; 2003 Oct; 7(5):613-22. PubMed ID: 14498824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Statins for treatment of CNS diseases. Status report from research and clinical practice].
    Menge T; von Büdingen HC; Zamvil SS; Hartung HP; Kieseier BC; Stüve O
    Nervenarzt; 2005 Apr; 76(4):426-37. PubMed ID: 15448914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tackling multiple sclerosis.
    Wekerle H
    Nature; 2002 Nov; 420(6911):39-40. PubMed ID: 12422206
    [No Abstract]   [Full Text] [Related]  

  • 7. Statins in the treatment of central nervous system autoimmune disease.
    Weber MS; Youssef S; Dunn SE; Prod'homme T; Neuhaus O; Stuve O; Greenwood J; Steinman L; Zamvil SS
    J Neuroimmunol; 2006 Sep; 178(1-2):140-8. PubMed ID: 16860400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins as potential therapeutic agents in neuroinflammatory disorders.
    Stüve O; Youssef S; Steinman L; Zamvil SS
    Curr Opin Neurol; 2003 Jun; 16(3):393-401. PubMed ID: 12858078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases.
    Willey JZ; Elkind MS
    Arch Neurol; 2010 Sep; 67(9):1062-7. PubMed ID: 20837848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins--a cure-all for the brain?
    Menge T; Hartung HP; Stüve O
    Nat Rev Neurosci; 2005 Apr; 6(4):325-31. PubMed ID: 15803163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins and demyelination.
    Weber MS; Zamvil SS
    Curr Top Microbiol Immunol; 2008; 318():313-24. PubMed ID: 18219823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T lymphocytes as targets of statins: molecular mechanisms and therapeutic perspectives.
    Ghittoni R; Lazzerini PE; Pasini FL; Baldari CT
    Inflamm Allergy Drug Targets; 2007 Mar; 6(1):3-16. PubMed ID: 17352684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy.
    Nath N; Giri S; Prasad R; Singh AK; Singh I
    J Immunol; 2004 Jan; 172(2):1273-86. PubMed ID: 14707106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug Insight: using statins to treat neuroinflammatory disease.
    Weber MS; Prod'homme T; Steinman L; Zamvil SS
    Nat Clin Pract Neurol; 2005 Dec; 1(2):106-12. PubMed ID: 16932506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of atorvastatin in multiple sclerosis].
    Koh CS
    Nihon Rinsho; 2003 Aug; 61(8):1455-60. PubMed ID: 12962038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cholesterol-reducing medications-a new therapeutic option for multiple sclerosis? Statins as immunomodulators].
    Neuhaus O; Wiendl H; Kieseier BC; Archelos JJ; Hartung HP
    Nervenarzt; 2003 Aug; 74(8):704-7. PubMed ID: 12904873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pleiotropic effects of statins on the vascular tissue.
    Ikeda U; Shimada K
    Curr Drug Targets Cardiovasc Haematol Disord; 2001 Jun; 1(1):51-8. PubMed ID: 12769664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statins as novel immunomodulators: from cell to potential clinical benefit.
    Mach F
    Thromb Haemost; 2003 Oct; 90(4):607-10. PubMed ID: 14515180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statin-mediated protective effects in the central nervous system: general mechanisms and putative role of stress proteins.
    Schmeer C; Kretz A; Isenmann S
    Restor Neurol Neurosci; 2006; 24(2):79-95. PubMed ID: 16720944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulatory effects of HMG-CoA reductase inhibitors.
    Danesh FR; Anel RL; Zeng L; Lomasney J; Sahai A; Kanwar YS
    Arch Immunol Ther Exp (Warsz); 2003; 51(3):139-48. PubMed ID: 12894868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.